A CXCR4 targeting peptide delivered by silica nanoparticles eliminates migrating cancer stem cells in pancreatic ductal adenocarcinoma.
A CXCR4-targeting peptide just took a major step forward in pancreatic cancer research. Scientists found that loading the JM#21 peptide into silica nanoparticles wipes out migrating cancer stem cells (miCSCs) in pancreatic ductal adenocarcinoma—one of the toughest cancers out there.
Sci Rep
by Tiwary K, Lahusen A, Inaas S et al.
“A CXCR4 targeting peptide delivered by silica nanoparticles eliminates migrating cancer stem cells in pancreatic ductal adenocarcinoma. Tiwary K(1), Lahusen A(1), Inaas S(1), Beitzinger B(2), Schmid R(2), Harms M(3), Hauff S(1), Arnold F(4), Walter K(1), Alcala S(5)(6), Hahn S(7), Heßmann E(8), Kleger A(9), Azoitei N(9), Seufferlein T(1), Sainz B Jr(5)(6), Münch J(3), Lindén M(2), Hermann PC(10)(11). Author information: (1)Department of Internal Medicine I, Ulm University, Albert-Einstein-Allee 23, 89081, Ulm, Germany. (2)Institute for Inorganic Chemistry II, Ulm University, 89075, Ulm, Germany. (3)Department of Molecular Virology, Ulm University, 89081, Ulm, Germany. (4)Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY, 10021, USA. (5)Department of Cancer, Biomedical Research Institute (IIBM) Sols-Morreale, CSIC-UAM, 28029, Madrid, Spain. (6)Biomarkers and Personalized Approach to Cancer (BIOPAC) Group, Area 3 Cancer, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), 28029, Madrid, Spain. (7)Department of Internal Medicine, Ruhr University Bochum, 44801, Bochum, Germany. (8)Department of Gastroenterology, Gastrointestinal Oncology and Endocrinology, University Medical Center Göttingen, 37075, Göttingen, Germany. (9)Institute of Molecular Oncology and Stem Cell Biology, Ulm University, 89081, Ulm, Germany. (10)Department of Internal Medicine I, Ulm University, Albert-Einstein-Allee 23, 89081, Ulm, Germany. patrick.hermann@uni-ulm.de. (11)Department of Emergency Medicine, Schwarzwald-Baar Hospital, 78052, Villingen-Schwenningen, Germany. patrick.hermann@uni-ulm.de. Pancreatic ductal adenocarcinoma (PDAC) is among the most aggressive and metastatic malignancies worldwide. Migrating cancer stem cells (miCSCs), marked by CD133⁺CXCR4⁺ expression is a key driver of PDAC progression, which currently lack effective therapeutic targets. Activated pancreatic stellate cells (PSCs) within the tumor microenvironment secrete CXCL12, the ligand for CXCR4, thereby promoting stemness, epithelial-to-mesenchymal transition (EMT), and chemoresistance in miCSCs. Despite advances in understanding PDAC biology, clinically effective strategies that target CXCR4⁺ CSC populations remain limited. In order to investigate the molecular mechanisms sustaining miCSCs, we performed protein-protein interaction network analysis, which identified the transcription factor BMI1 as a key downstream effector of the CXCL12/CXCR4 axis. Functional studies using shRNA-mediated knockdown of CXCR4 and BMI1 were conducted to assess their roles in miCSC migration, EMT, and self-renewal. We further evaluated the therapeutic potential of the endogenous CXCR4 antagonist EPI-X4 and its optimized derivative JM#21 in PDAC cell lines. We addressed the peptide stability by encapsulating JM#21 into mesoporous silica nanoparticles (MSNs) designed for improved half-life and sustained release under physiological conditions. BMI1 was confirmed as a critical mediator of CXCL12/CXCR4-driven stemness and EMT. Knockdown of CXCR4 or BMI1 significantly impaired miCSC maintenance and migration towards CXCL12. Both EPI-X4 and JM#21 potently inhibited CXCL12-mediated signaling, reduced EMT and stemness markers, and suppressed miCSC migratory potential. JM#21 displayed superior efficacy and re-sensitized previously resistant PDAC cell lines to gemcitabine and paclitaxel. Functional assays demonstrated that nanoparticle-loaded JM#21 more effectively suppressed EMT markers and self-renewal than the free peptide, highlighting the advantage of nanoparticle delivery in therapeutic applications. Given their biocompatibility and modularity, silica nanoparticles offer a promising platform for stabilizing peptide drugs. Our findings reveal that tumor-stroma crosstalk via the CXCL12/CXCR4/BMI1 axis plays a central role in sustaining miCSC-driven metastasis and therapy resistance in PDAC. Targeting this signaling pathway with nanoparticle-stabilized JM#21 represents a novel and clinically promising therapeutic strategy to disrupt PDAC progression and improve the efficacy of existing combination treatments. © 2026. The Author(s). Conflict of interest statement: Competing interests: M.H., and J.M. are co-inventors of pending and issued patents that claim to use EPI-X4 (ALB408-423) and derivatives for the therapy of CXCR4-associated diseases. All other Authors have no competing interests to declare. Consent for publication: Not applicable. Ethical approval and consent to participate: The patient derived xenograft used in this study were obtained under the Material Transfer Agreement with Spanish National Cancer Center (CNIO), Madrid, Spain (Reference no. I409181220BSMH and I405271505PHMH) followed by the ethics committee approval of Ulm University (161/15 – The role of circulating cancer stem cells in EMT and Metastasis). The patient derived organoids were obtained by the biobank of the University Hospital of Ulm followed by the ethics committee approval of Ulm University (72/2019: PDAC Liver Metastasis) and (67/2019: human tissue and blood).”
Here’s what matters: miCSCs fuel metastasis and resistance in this cancer. They’re marked by CD133⁺CXCR4⁺ and are basically the escape artists of the tumor world. Until now, effective ways to shut them down have been limited. Researchers discovered that the tumor microenvironment feeds these cells through the CXCL12/CXCR4/BMI1 axis. Targeting this axis is the key to stopping cancer spread and resistance.
The team zeroed in on JM#21, a peptide derivative of the natural CXCR4 antagonist EPI-X4. The catch? Peptides can break down quickly in the body. So, they encapsulated JM#21 in mesoporous silica nanoparticles. This boosted its stability and allowed a slow, steady release.
Key findings:
CXCR4 or BMI1 knockdown halts miCSC migration and self-renewal.
Both EPI-X4 and JM#21 block the signals that make these cells so aggressive.
JM#21, especially when delivered via nanoparticles, outperforms the free peptide. It slashes EMT markers (that’s the stuff that turns cells invasive) and even makes cells more responsive to standard chemo.
Silica nanoparticles aren’t just a random delivery vehicle. Their biocompatibility and tunability make them a sharp choice for stabilizing research peptides.
For researchers exploring new peptide-based tools, this is a real proof-of-concept. Nanoparticle delivery isn’t just hype; it moves the needle for targeting tough cell populations. More on this and related advances can be found in our peptide research index.
Peptide research keeps pushing boundaries—don’t overlook delivery tech when designing your next experiment.
Related Reading
The STRIDE Trial and Semaglutide: Implications for Clinical Vascular Practice.
News · J Med ChemStructure-Based Adaptation of a SARS-CoV-2 Neutralizing Peptide to New Virus Variants.
News · J Nucl MedCombining an α(v)β(6)-Targeted (177)Lu-Based Peptide Receptor Radionuclide Therapy with Olaparib to Boost Therapeutic Efficacy in Pancreatic Cancer.
For Research Use Only
All content published on Pushing Peptides is intended for educational and informational purposes only. The information provided is not intended as medical advice, diagnosis, or treatment. Peptides discussed in this article are research compounds and are not approved for human therapeutic use by the FDA or any other regulatory agency. All studies referenced involve animal models or in vitro research unless otherwise stated. Consult a qualified healthcare professional before making any decisions related to your health. Pushing Peptides does not sell peptides — we are a vendor directory and educational resource.